Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

943

Enrollment

INDUSTRY

Sponsor class

Stopped Unfavourable benefit:risk

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG: Placebo ELLIPTA
DRUG: Nemiralisib ELLIPTA 50 µg
DRUG: Nemiralisib ELLIPTA 100 µg
DRUG: Nemiralisib ELLIPTA 250 µg
DRUG: Nemiralisib ELLIPTA 500 µg
DRUG: Nemiralisib ELLIPTA 750 µg
DRUG: Albuterol (Salbutamol) MDI or nebules
DRUG: Standard of care therapy

Sponsor

GlaxoSmithKline